These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 19008592)
1. Acute erythroid toxicity in visceral leishmaniasis: a rare complication of antimonial therapy. Sharma S; Malhan P; Pujani M; Rath B Indian J Pathol Microbiol; 2008; 51(4):546-7. PubMed ID: 19008592 [TBL] [Abstract][Full Text] [Related]
2. Antimony-induced cerebellar ataxia. Khalil EA; Ahmed AE; Musa AM; Hussein MH Saudi Med J; 2006 Jan; 27(1):90-2. PubMed ID: 16432602 [TBL] [Abstract][Full Text] [Related]
3. Cumulative cardiac toxicity of sodium stibogluconate and amphotericin B in treatment of kala-azar. Maheshwari A; Seth A; Kaur S; Aneja S; Rath B; Basu S; Patel R; Dutta AK Pediatr Infect Dis J; 2011 Feb; 30(2):180-1. PubMed ID: 20823781 [TBL] [Abstract][Full Text] [Related]
4. Case report: Acute renal injury as a result of liposomal amphotericin B treatment in sodium stibogluconate unresponsive visceral leishmaniasis. Zhao S; Zhang D; Li L; Mao Q Am J Trop Med Hyg; 2011 Dec; 85(6):1035-7. PubMed ID: 22144439 [TBL] [Abstract][Full Text] [Related]
7. Post-treatment fulminant hepatic failure in an infant with Visceral leishmaniasis: Immune injury or stibogluconate toxicity? Baranwal AK; Ravi RN; Singh R Indian J Pediatr; 2010 Jan; 77(1):107-8. PubMed ID: 19936650 [No Abstract] [Full Text] [Related]
8. Leishmania species, drug unresponsiveness and visceral leishmaniasis in Bihar, India. Thakur CP; Dedet JP; Narain S; Pratlong F Trans R Soc Trop Med Hyg; 2001; 95(2):187-9. PubMed ID: 11355558 [TBL] [Abstract][Full Text] [Related]
9. Acute pancreatitis associated with sodium stibogluconate treatment in a patient with human immunodeficiency virus. Domingo P; Ferrer S; Kolle L; Muñoz C; Rodriguez P Arch Intern Med; 1996 May; 156(9):1029, 1032. PubMed ID: 8624172 [No Abstract] [Full Text] [Related]
10. A comparison of liposomal amphotericin B with sodium stibogluconate for the treatment of visceral leishmaniasis in pregnancy in Sudan. Mueller M; Balasegaram M; Koummuki Y; Ritmeijer K; Santana MR; Davidson R J Antimicrob Chemother; 2006 Oct; 58(4):811-5. PubMed ID: 16916865 [TBL] [Abstract][Full Text] [Related]
11. Magnitude of unresponsiveness to sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar. Das VN; Ranjan A; Bimal S; Siddique NA; Pandey K; Kumar N; Verma N; Singh VP; Sinha PK; Bhattacharya SK Natl Med J India; 2005; 18(3):131-3. PubMed ID: 16130613 [TBL] [Abstract][Full Text] [Related]
12. [Acute pancreatitis due to antimonials in patients with visceral leishmaniasis and HIV infection]. Cortés E; Ribera E; Cucurull E; de Otero J; Ocaña I; Pahissa A Med Clin (Barc); 1995 Apr; 104(15):578-80. PubMed ID: 7769868 [TBL] [Abstract][Full Text] [Related]
13. Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar, India, justify its continued use as a first-line drug? An observational study of 80 cases. Thakur CP; Sinha GP; Pandey AK; Kumar N; Kumar P; Hassan SM; Narain S; Roy RK Ann Trop Med Parasitol; 1998 Jul; 92(5):561-9. PubMed ID: 9797829 [TBL] [Abstract][Full Text] [Related]
14. Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompetent patients. Minodier P; Retornaz K; Horelt A; Garnier JM Fundam Clin Pharmacol; 2003 Apr; 17(2):183-8. PubMed ID: 12667228 [TBL] [Abstract][Full Text] [Related]
15. Sodium stibogluconate-sensitive visceral leishmaniasis in the non-endemic hilly region of Uttarakhand, India. Verma SK; Ahmad S; Shirazi N; Kusum A; Kaushik RM; Barthwal SP Trans R Soc Trop Med Hyg; 2007 Jul; 101(7):730-2. PubMed ID: 17382981 [TBL] [Abstract][Full Text] [Related]
16. Visceral leishmaniasis in the BALB/c mouse: antimony tissue disposition and parasite suppression after the administration of free stibogluconate. Collins M; Carter KC; Baillie AJ Ann Trop Med Parasitol; 1992 Feb; 86(1):35-40. PubMed ID: 1319700 [TBL] [Abstract][Full Text] [Related]
17. Pentavalent antimony-mannan conjugate therapy of experimental visceral leishmaniasis. Roberts WL; Hariprashad J; Rainey PM; Murray HW Am J Trop Med Hyg; 1996 Oct; 55(4):444-6. PubMed ID: 8916804 [TBL] [Abstract][Full Text] [Related]
18. Antimonial treatment of visceral leishmaniasis: are current in vitro susceptibility assays adequate for prognosis of in vivo therapy outcome? Rijal S; Yardley V; Chappuis F; Decuypere S; Khanal B; Singh R; Boelaert M; De Doncker S; Croft S; Dujardin JC Microbes Infect; 2007 Apr; 9(4):529-35. PubMed ID: 17350306 [TBL] [Abstract][Full Text] [Related]
19. Visceral leishmaniasis: a rare cause of post-transplant fever and pancytopenia. Rajaram KG; Sud K; Kohli HS; Gupta KL; Sakhuja V J Assoc Physicians India; 2002 Jul; 50():979-80. PubMed ID: 12126362 [TBL] [Abstract][Full Text] [Related]
20. [Treatment of visceral leishmaniasis in children]. Minodier P; Noël G; Blanc P; Uters M; Retornaz K; Garnier JM Med Trop (Mars); 2007 Feb; 67(1):73-8. PubMed ID: 17506279 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]